Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation

Andersen, Barbara L.; DeRubeis, Robert J.; Berman, Barry S.; Gruman, Jessie; Champion, Victoria L.; Massie, Mary Jane; Holland, Jimmie C.; Partridge, Ann H.; Bak, Kate; Somerfield, Mark R.; Rowland, Julia H.

doi:10.1200/jco.2013.52.4611

Cited by 620 publications

(555 citation statements)

References 77 publications

Supporting

Mentioning

522

Contrasting

Unclassified

Order By: Relevance

“…27 The fact that CAT measures were not captured demonstrates that there may be newer, but well-validated, measures that have not yet generated enough research to have been captured in a review. 27,67 The PHQ-9 is another good example, because while it was reviewed less favourably in this meta-review, recent research suggests it may be a promising screener 12 and case-finder, 68 and may be quite responsive. 69 The captured reviews also provided different data and used different methods, making it difficult to draw firm conclusions, however future meta-reviews could utilize more sophisticated tools (such as Rasch measurement) to allow a common metric to be generated for different depression measures.…”

Section: Meta-review Limitationsmentioning

confidence: 99%

“…5,6 Mirroring this rise, clinicians and researchers have utilized numerous patient-reported outcome measures to assess depression in individuals affected by cancer. 4,7,8,9 Unrecognized and untreated depression can have deleterious implications for long term quality of life, 11,12 treatment adherence 13 health service use, 14,15 requests for death, 11 and mortality. [16][17][18] Opinion leaders therefore often recommend that all patients be evaluated for depressive symptoms at regular intervals across the trajectory of cancer care.…”

Section: Introductionmentioning

confidence: 99%

“…[16][17][18] Opinion leaders therefore often recommend that all patients be evaluated for depressive symptoms at regular intervals across the trajectory of cancer care. 12 Accurate and timely measurement of depression can ensure that the prevalence of depression across populations and stages is neither under-nor over-estimated. 19,20 This data is needed to inform clinical practice and the allocation of appropriate resources to psychosocial services.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Patient-reported depression measures in cancer: a meta-review

Wakefield

Butow

Aaronson

et al. 2015

The Lancet Psychiatry

View full text Add to dashboard Cite

SummaryDepression measurement in cancer care is complex and inconsistent. It is difficult for investigators to select the best-performing tool. We conducted a meta-review to integrate the findings of reviews of patient-report depression measures used as screeners or case-finders in oncology. We searched Medline, PsycINFO, EMBASE and grey literature from 1999-2014. We identified 19 reviews representing 372 primary studies assessing more than 50 depression measures. We used 11 highquality reviews to guide our analysis, which was organized by measurement goal and target population. The Hospital Anxiety Depression Scale was the most recommended, and criticized, depression screener. Few reviews evaluated casefinding performance or measure responsiveness, or measure suitability for particular populations. This meta-review demonstrates that the available measure selection advice is conflicting. By being fully cognizant of the benefits and limitations of depression measurement, investigators can improve the accuracy of their data and achieve more sophisticated interpretations of their findings.

show abstract

Section: Meta-review Limitationsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patient-reported depression measures in cancer: a meta-review

Wakefield

Butow

Aaronson

et al. 2015

The Lancet Psychiatry

View full text Add to dashboard Cite

show abstract

“…The PHQ-9 was selected based on its wide use in medical populations (Manea, Gilbody, & McMillan, 2012), established severity ranges and sensitivity to change , specific recommendation in guidelines for management of depression in cancer patients (Andersen et al, 2014) and inclusion of somatic symptoms, which are recognised as a core domain of depression, not confounding diagnosis in cancer survivors (Mitchell, Lord, & Symonds, 2012). In non-cancer populations, scores from 10 to 14 indicate mild-moderate depression; 15-19 moderately severe (Kroenke et al, 2001).…”

Section: Effectiveness Outcomesmentioning

confidence: 99%

Phase II trial of a depression self-care intervention for adult cancer survivors

et al. 2017

View full text Add to dashboard Cite

Supported self-care interventions are a low-intensity treatment for depression that has received little research attention in the cancer population. This is a phase II intervention only study to test the feasibility, acceptability and preliminary effectiveness of a depression self-care intervention for cancer patients who have completed their primary treatment and have moderate depressive symptoms. The self-care intervention was adapted from a successful model for people with chronic physical conditions, following focus groups with cancer care professionals and patients. The support was delivered by telephone by a trained lay coach who provided up to 8 weekly coaching contacts. A variety of recruitment methods were tested; those with the highest yield of eligible subjects per research staff time were electronic mailings to community support group members and social media posting. Sixty-eight people were contacted about the study over an 11-month period, of whom 34 (49%) were eligible; 32 were enrolled (94% recruitment rate); and 25 completed 2-month follow-up (78% retention). The mean severity of PHQ-9 depression decreased significantly from screening to 2 months (12.8 to 7.0, p < .0001). The intervention is a promising treatment option for cancer survivors, demonstrating sufficient effectiveness and feasibility to proceed with a phase III clinical trial. K E Y W O R D Scancer survivorship, depression, feasibility, intervention, self-care, self-management

show abstract

“…40 Lastly, data were collected during 2008 and 2009. As such, current treatments may potentially produce slightly different symptom profiles than those described in our sample.…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Depression—A Major Contributor to Poor Quality of Life in Patients With Advanced Cancer

Grotmol

Lie

Hjermstad

et al. 2017

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Context: Quality of life (QoL) and depression are important patient-reported outcomes in cancer care. However, the relative importance of depression severity in predicting QoL remains unclear due to few methodologically sound studies. Objectives:To examine whether depression contributes to impairment of QoL irrespective of prognostic factors and symptom burden.Methods: 563 patients were included from the European Palliative Care Research Collaborative Study (EPCRC-CSA), an international, multi-centre, cross-sectional study. The relative importance of prognostic factors (systemic inflammation (mGPS), co-morbidities and physical performance (KPS), symptom burden (loss of appetite, breathlessness, nausea (ESAS) and pain (BPI)) and depression severity (PHQ-9) in predicting Global Health/QoL (EORTC-QLQ-C30) were assessed using hierarchical multiple regression models.Results: 55% were females, median age 64 years, 87% had metastatic disease, Conclusion:Depression severity was the strongest single predictor of poorer QoL in this sample of patients with advanced cancer, after accounting for a wide range of clinically relevant variables. Future studies should investigate the contribution of psychosocial variables on QoL. Our findings emphasize the importance of managing depression to achieve the best possible QoL for these patients.

show abstract

Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation

Cited by 620 publications

References 77 publications

Patient-reported depression measures in cancer: a meta-review

Patient-reported depression measures in cancer: a meta-review

Phase II trial of a depression self-care intervention for adult cancer survivors

Depression—A Major Contributor to Poor Quality of Life in Patients With Advanced Cancer

Contact Info

Product

Resources

About